| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/02/2004 | US20040241239 Mixed complexes for masking the taste of bitter active substances |
| 12/02/2004 | US20040241236 shell provides a delay of greater than one hour for the onset of dissolution of the active ingredient upon contacting of the dosage form with a liquid medium such as water or gastrointestinal fluids, and the delay is independent of the pH |
| 12/02/2004 | US20040241235 Core of drug and binder having at least three successive coating layers starting from the core: a delayed or sustained release polymeric coating; a hydrophobic coating containing a waxy compound; and another polymeric coating having a complementary release function and conditioning the suspension medium |
| 12/02/2004 | US20040241232 Comprising inhalable medicament particles having a mass median aerodynamic diameter no greater than 10 mu m and 50% of a non-respirable excipient fraction comprising low density excipient particles having an aerodynamic diameter greater than 10 mu m and a geometric diameter greater than 30 mu m |
| 12/02/2004 | US20040241228 Spirolaxine acts as active principle in association with all-trans retinoic acid for treatment of those pathologies responding to activation of PPAR gamma receptor, such as acute malignant haemopathies. and Type 2 insulin-resistant diabetes |
| 12/02/2004 | US20040241227 1900 to 2600 mg amoxycillin and an amount of potassium clavulanate such that the weight ratio of amoxycillin to clavulanate is 2:1 to 20:1, at a dosage regiment/interval of about 12 hours; pharmacokinetics; time release |
| 12/02/2004 | US20040241226 Administering a tyrosine kinase inhibitor, more particularly a non toxic, potent and selective c-kit inhibitor, wherein said inhibitor is unable to promote death of IL-3 dependent cells cultured to presence of IL-3 |
| 12/02/2004 | US20040241225 Modulation of vitamin storage |
| 12/02/2004 | US20040241224 Administering cis-clomiphene and trans-clomiphene or analogs or pharmaceutically acceptable salts or solvates thereof wherein the ratio of trans-clomiphene and cis-clomiphene is greater than 1; treatment of hypogonadism |
| 12/02/2004 | US20040241220 R(-)N-methyl-N-(prop-2-ynyl)-2-aminophenylpropane; oral, transdermal, or injection drug delivery |
| 12/02/2004 | US20040241219 System comprising back layer, protective layer and at least one active-compound-containing polymer matrix comprising a polyacrylate which contains extremely reduced number of functional groups; in one embodiment polyacrylate is free of hydroxyl and/or carboxyl groups |
| 12/02/2004 | US20040241217 Method for administration of immune modulators in systemic and localized immune disorders |
| 12/02/2004 | US20040241208 Comprising an active ingredient and a carbohydrate, at least a portion of which carbohydrate is crystallized and has an average particle size of 2 to 35 microns, composition having a moisture content of 10 to 13 percent; soft tablet |
| 12/02/2004 | US20040241206 Use of nanoparticles as carriers for biocides in ophthalmic compositions |
| 12/02/2004 | US20040241205 capsules comprising biocompatible silica sol-gel matrices that encapsulate chemical intermediates or prodrugs that convert when contacted with tissues and/or fluids; grafting encapsulated L-amino acid decarboxylase in the brain to convert L-dopa to dopamine for prophylaxis of Parkinson's disease |
| 12/02/2004 | US20040241204 Sustained release pharmaceutical composition |
| 12/02/2004 | US20040241197 Creatinine and derivatives used as stabilizers for creatine and derivatives; treatment and prophylaxis of ultraviolet radiation and/or ozone-induced skin damage, inflammatory and degenerative skin conditions, of sensitive or dry skin, of skin aged in a natural way, of damage by photoaging; pruritus |
| 12/02/2004 | US20040241192 Administering a tryptanthrin compound, e.g., 8-nitroindolo[2,1-b]quinazoline-6,12-dione, to potentiate the immune response to an antigen; immunostimulants; small molecule immune potentiators; immunotherapy for infectious diseases; anticarcinogenic agents; vaccine adjuvant compositions and kits |
| 12/02/2004 | US20040241182 lymphocytes; immunogens; fusion proteins; for treatment/prevention of infection |
| 12/02/2004 | US20040241168 Compositions and methods for the treatment and clinical remission of psoriasis |
| 12/02/2004 | US20040241167 CD4/CD25 antigen containing cell, interleukin, CD8/CD28 antigen containing cell, and vitamin D3; for generating tolerogenic antigen-presenting cell; kits; for treatment of autoimmune diseases such as AIDS, cancer, and Hepatitis C-related disorders |
| 12/02/2004 | US20040241166 Use of inhibitors of ikk-beta and method for discovery of said inhibitors |
| 12/02/2004 | US20040241159 Serotonin receptor antagonists, analgesic (aspirin), and antiemitic; treating cephalic pain such as migraine, cluster headache, chronic paroxysmal hermicrania, headache associated with vascular disorders, headache associated with substances or their withdrawl, rebound headache and tension headache |
| 12/02/2004 | US20040241135 Therapeutic compositions including bio-availability enhancers |
| 12/02/2004 | US20040241134 Colon cleansing compositions and methods of use therefor |
| 12/02/2004 | US20040241125 Cosmetic composition comprising at least one film-forming polymer and at least one regulator |
| 12/02/2004 | US20040241103 Propellant particles of first drug suspended in propellant; second drug dissolved in aerosol forms |
| 12/02/2004 | US20040241100 Nasally administrable compositions of zolpidem and methods of use |
| 12/02/2004 | US20040241094 Oily paclitaxel composition and formulation for chemoembolization and preparation method thereof |
| 12/02/2004 | US20040241087 Enzyme inhbitors; diagnosis, therapy; antitumor agents, anticancer agents; breast cancer; using a steroid |
| 12/02/2004 | US20040238781 Using genistein; preadministering before exposure to radiation; prevent tissue damage |
| 12/02/2004 | DE202004013365U1 Nasal spray for treatment of acute and/or chronic nose cavity inflammation contains vitamin C dissolved in a carrier substance |
| 12/02/2004 | DE202004009180U1 Formulation comprising glycine-containing gel, useful, by external or internal application, for treatment or prevention of e.g. allergy, sunburn and stress |
| 12/02/2004 | DE10322293A1 Post-wetting agent contains substances for supplying cornea of human eye |
| 12/02/2004 | DE10322108A1 Antiandrogene Pyrrolidine mit tumorhemmender Wirksamkeit Antiandrogens pyrrolidines with antitumor efficacy |
| 12/02/2004 | DE10321725A1 Enzymhaltige Zusammensetzungen, daraus hergestellte diätetische Lebensmittel und Arzneimittel und ihre Verwendung für medizinische Zwecke Enzyme-containing compositions, dietetic foods and medicines prepared therefrom and their use for medical purposes |
| 12/02/2004 | DE10308353A1 Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Diarylcycloalkylderivate, processes for their preparation and their use as medicaments |
| 12/02/2004 | CA2634766A1 Pharmaceutical composition containing histone deacetylase inhibitor |
| 12/02/2004 | CA2634765A1 Pharmaceutical composition containing histone deacetylase inhibitor |
| 12/02/2004 | CA2634709A1 Pharmaceutical composition containing histone deacetylase inhibitor |
| 12/02/2004 | CA2532059A1 Triaza-spiro compounds as nociceptin analogues and uses thereof |
| 12/02/2004 | CA2528521A1 Disease prevention and vaccination prior to thymic reactivations |
| 12/02/2004 | CA2527191A1 Cancer treatment comprising a histone deacetylase inhibitor and another anticancer agent |
| 12/02/2004 | CA2526908A1 Combination of histone deacetylase inhibitors with chemotherapeutic agents |
| 12/02/2004 | CA2526661A1 Diagnostic kit for liver cirrhosis comprising an antibody specific for human protooncogenic protein |
| 12/02/2004 | CA2526651A1 Immunosuppressive effects of pteridine derivatives |
| 12/02/2004 | CA2526637A1 Carboxylic acid compound and medecine comprising the same |
| 12/02/2004 | CA2526631A1 Migraine remedy |
| 12/02/2004 | CA2526493A1 Means for preventing and treating cellular death and their biological applications |
| 12/02/2004 | CA2526393A1 Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer |
| 12/02/2004 | CA2526374A1 2-aminoquinoline derivatives |
| 12/02/2004 | CA2526349A1 A method of treating or preventing chronic wounds and a complete nutritional composition comprising glycine and/or leucine for use therein |
| 12/02/2004 | CA2526289A1 Combination chemotherapy comprising 5-fluorouracil or a derivative thereof and a liposomal platinum complex |
| 12/02/2004 | CA2526278A1 Combination chemotherapy comprising a liposomal platinum complex |
| 12/02/2004 | CA2526222A1 Treatment of respiratory disease associated with matrix metalloprotease inhibitors |
| 12/02/2004 | CA2526212A1 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents |
| 12/02/2004 | CA2526201A1 Glycosaminoglycans for treatment emotional dysfunctions |
| 12/02/2004 | CA2526173A1 Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity |
| 12/02/2004 | CA2526027A1 Process for making spirolactone compounds |
| 12/02/2004 | CA2526013A1 Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists |
| 12/02/2004 | CA2525946A1 Composition comprising a pde4 inhibitor and a pde5 inhibitor |
| 12/02/2004 | CA2525945A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i |
| 12/02/2004 | CA2525943A1 Salmeterol and ciclesonide combination |
| 12/02/2004 | CA2525934A1 Thiocarbamate inhibitors of alpha-4 integrins |
| 12/02/2004 | CA2525840A1 Ovr115 antibody composition and methods of use |
| 12/02/2004 | CA2525804A1 Use of chondroitinase abc enzyme for the treatment of cns injuries |
| 12/02/2004 | CA2525789A1 Compositions containing a combination of a pharmaceutical agent or a cosmetic agent and an oxy group-bearing aromatic aldehyde |
| 12/02/2004 | CA2525571A1 Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to thecentral nervous system |
| 12/02/2004 | CA2525557A1 Methods for treating cancers using polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidene-2,6-dione |
| 12/02/2004 | CA2525501A1 Tetrahydroisoquinoline derivatives as ppar-.alpha. activators |
| 12/02/2004 | CA2525310A1 Aryl-carbaldehyde oxime derivatives and their use as estrogenic agents |
| 12/02/2004 | CA2525292A1 Phenyl quinolines and their use as estrogenic agents |
| 12/02/2004 | CA2525280A1 Compositions for the treatment of reduced blood flow |
| 12/02/2004 | CA2525277A1 Method for augmenting the antitumor activity of anti-cancer agents |
| 12/02/2004 | CA2525168A1 Compositions for delivering peptide yy and pyy agonists |
| 12/02/2004 | CA2525130A1 Improved cytotoxic agents comprising new maytansinoids |
| 12/02/2004 | CA2525102A1 Benzothiazole derivatives and use thereof in the treatment of diseases relates to the adenosine a2a receptor |
| 12/02/2004 | CA2525012A1 Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases |
| 12/02/2004 | CA2524950A1 Methods for facilitating recovery of functions of endogenous or implanted or transplanted stem cells using high molecular weight hyaluronic acid |
| 12/02/2004 | CA2524948A1 Novel pyridopyrazines and use thereof as kinase inhibitors |
| 12/02/2004 | CA2524870A1 Pharmaceutical combination comprising modafinil and another drug |
| 12/02/2004 | CA2524868A1 Topical treatment of skin conditions |
| 12/02/2004 | CA2524538A1 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
| 12/02/2004 | CA2524531A1 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 12/02/2004 | CA2524116A1 Antiarthritic combinations |
| 12/02/2004 | CA2524047A1 Immunosuppressant compounds and compositions |
| 12/02/2004 | CA2523467A1 Treatment of t-cell mediated diseases |
| 12/02/2004 | CA2521575A1 Antibiotic composition |
| 12/02/2004 | CA2489124A1 Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof |
| 12/01/2004 | EP1482038A1 Novel protein and dna thereof |
| 12/01/2004 | EP1481989A1 A-33 related antigens and their pharmacological uses |
| 12/01/2004 | EP1481983A1 Nucleoside analogues and oligonucleotide derivative comprising nucleotide analogue thereof |
| 12/01/2004 | EP1481975A1 Inhibitors of farnesyl protein transferase |
| 12/01/2004 | EP1481969A1 Piperidine derivative compounds and drugs containing the compounds as the active ingredient |
| 12/01/2004 | EP1481966A1 Novel arylamidine derivative or salt thereof |
| 12/01/2004 | EP1481964A1 Stable salts of novel derivatives of 3,3-diphenylpropylamines |
| 12/01/2004 | EP1481962A1 New cholesterolemia-lowering carboxyalkylether compound |
| 12/01/2004 | EP1481690A1 Therapeutic compositions including bio-availability enhancers |
| 12/01/2004 | EP1481689A1 Hair growth stimulants, percutaneous preparations and method of stimulating hair growth |
| 12/01/2004 | EP1481682A1 Preparation that contains oligosaccharides and probiotics |